A pharmaceutical formulation of the naturally occurring human peptide angiotensin-(1-7), being developed for the treatment of Duchenne Muscular Dystrophy-associated Cardiomyopathy, ischemic stroke recovery, and other conditions.

A platform focused on developing small molecule agonists that target the Mas and MrgD receptors of the Alternative Renin-Angiotensin System for treating diseases characterized by tissue fibrosis and endothelial damage.